Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Serina Therapeutics, Inc. (SER) had Normalized Income after Taxes of $-6.36M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-8.93M |
|
-- |
|
-- |
|
$6.78M |
|
$-6.78M |
|
$0.43M |
|
$-6.36M |
|
$-6.36M |
|
$-6.36M |
|
$-6.36M |
|
$-6.36M |
|
|
Normalized Income after Taxes |
$-6.36M |
$-6.78M |
|
$-6.69M |
|
16.39M |
|
16.39M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$25.03M |
|
$0.48M |
|
$0.78M |
|
$25.81M |
|
$3.76M |
|
$3.09M |
|
$3.32M |
|
$7.08M |
|
$18.73M |
|
$18.73M |
|
$18.73M |
|
25.40M |
|
| Cash Flow Statement Financials | |
$-11.25M |
|
$-0.05M |
|
$31.26M |
|
$3.06M |
|
$23.02M |
|
$19.97M |
|
$2.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.65 |
|
-- |
|
-- |
|
0.14 |
|
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.93% |
|
-33.93% |
|
-24.62% |
|
-29.13% |
|
$0.74 |
|
$-0.69 |
|
$-0.69 |
|